No Data
No Data
Express News | Oragenics, Inc. Announces Health and Disability Ethics Committee Submission for Phase Iia Concussion Trial
Oragenics, Inc. Announces Health and Disability Ethics Committee Submission for Phase IIa Concussion Trial
Oragenics, Inc. Participates in the 3rd Nasal Formulation & Delivery Summit
12 Health Care Stocks Moving In Wednesday's After-Market Session
Oragenics, Inc. Provides Q1 2025 Shareholder Update on Strategic and Financial Progress
Oragenics, Inc. Announces Filing of 2024 Annual Report on Form 10-K